Structured evidence table for Royal Jelly Cardiometabolic Meta-Analysis, generated from 1 reusable source document in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Royal Jelly Cardiometabolic Meta-Analysis | Such interventions can help refine dietary and clinical guidelines, especially for individuals at high risk of NCDs []. | 1 | Norouzzadeh Mostafa (2025) | Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis |
| Royal Jelly Cardiometabolic Meta-Analysis | A 2023 meta-analysis reported that honey improved blood glucose and lipid parameters but also increased pro-inflammatory markers [], whereas a 2021 SRMA found no significant effect on lipid profiles []. | 1 | Norouzzadeh Mostafa (2025) | Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis |
| Royal Jelly Cardiometabolic Meta-Analysis | found no general effect on anthropometric indices, but RJ at doses <3000 mg/day significantly improved anthropometric indices []. | 1 | Norouzzadeh Mostafa (2025) | Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis |
| Royal Jelly Cardiometabolic Meta-Analysis | 1 2 1 3 Non-communicable diseases (NCDs) are responsible for an estimated 43 million deaths annually, disproportionately affecting low- and middle-income countries where nearly 73% of global NCDs-related mortality was recorded []. | 1 | Norouzzadeh Mostafa (2025) | Dosage exploration of the effects of honey and its derivatives on cardiometabolic outcomes: an overview of systematic reviews and GRADE-assessed updated meta-analysis |
Source documents